Physician profile
Caleb Richards
NPI 1508216490
$4,833.99
in general payments reported to CMS, 2019-2025
32 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.34 · 2020: $43.90 · 2021: $244 · 2022: $800 · 2023: $1,236 · 2024: $1,302 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,672.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,150.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $594.94 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $537.94 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $395.85 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $288.50 | 2023-2025 | |
| Exact Sciences Corporation | $268.78 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $259.55 | 2023-2025 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $222.15 | 2022-2025 | |
| Abbott Laboratories | $209.63 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $125.13 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.22 | 2023-2025 | Jardiance |
| Corcept Therapeutics | $89.32 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $80.61 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $60.48 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $49.92 | 2022-2023 | Spravato |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.80 | 2025 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.92 | 2024-2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $32.00 | 2022-2023 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $28.86 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $28.37 | 2022 | |
| Cequr Corporation | $28.28 | 2024 | Cequr Simplicity |
| Daiichi Sankyo INC. | $27.46 | 2025 | Injectafer |
| Gilead Sciences, INC. | $23.71 | 2025 | |
| Dynavax Technologies Corporation | $22.82 | 2023 | Heplisav-B |
| Lundbeck LLC | $22.06 | 2023 | Vyepti |
| Cvrx, INC. | $21.14 | 2024 | Barostim Neo System |
| Shield Therapeutics INC | $15.48 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.17 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.15 | 2023 | Eliquis |
| Alk-Abello, INC | $15.10 | 2024 | Ragwitek, Odactra, Grastek |
| Azurity Pharmaceuticals, INC. | $14.08 | 2023 | Horizant |
| Impel Pharmaceuticals INC. | $13.20 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.